While the second Risperdal trial resulted in a verdict favoring drugmaker Janssen Pharmaceuticals, the company was still found negligent in failing to warn—as it was in the first trial—leading some attorneys to speculate that Janssen will focus less on failure to warn defenses and more on the individual facts of each case.
Additionally, observers said that given the different results of each case, and the fact that only two have been tried, it’s still too early to definitively predict the direction of the litigation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
